BRPI0509504A - compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos - Google Patents
compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativosInfo
- Publication number
- BRPI0509504A BRPI0509504A BRPI0509504-2A BRPI0509504A BRPI0509504A BR PI0509504 A BRPI0509504 A BR PI0509504A BR PI0509504 A BRPI0509504 A BR PI0509504A BR PI0509504 A BRPI0509504 A BR PI0509504A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- amine compounds
- neurodegenerative disorders
- compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
COMPOSTOS DE TIADIAZOL-AMINA PARA O TRATAMENTO DE DISTúRBIOS NEURODEGENERATIVOS. A presente invenção refere-se a compostos da fórmula 1 onde R1, R3, R5 R7, X, Y e U (elevados) são como definidos. Os compostos de fórmula 1 possuem atividade para inibir a produção do peptídio Ab. A invenção também refere-se a composições farmacêuticas e métodos para o tratamento de doenças e distúrbios, por exemplo, distúrbios neurodegenerativos e/ou neurológicos, exemplo, mal Alzheimer, em um mamífero compreendendo compostos de fórmula 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55877704P | 2004-04-01 | 2004-04-01 | |
PCT/IB2005/000801 WO2005095368A1 (en) | 2004-04-01 | 2005-03-23 | Thiadiazole-amine compounds for the treatment of neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0509504A true BRPI0509504A (pt) | 2007-09-11 |
Family
ID=34962247
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0509504-2A BRPI0509504A (pt) | 2004-04-01 | 2005-03-23 | compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos |
Country Status (7)
Country | Link |
---|---|
US (1) | US7232820B2 (pt) |
EP (1) | EP1735294A1 (pt) |
JP (1) | JP2007530661A (pt) |
BR (1) | BRPI0509504A (pt) |
CA (1) | CA2561596A1 (pt) |
MX (1) | MXPA06011350A (pt) |
WO (1) | WO2005095368A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
RS50595B (sr) * | 2004-03-23 | 2010-05-07 | Pfizer Products Incorporated | Jedinjenja imidazola za lečenje neurodegenerativnih poremećaja |
US7354944B2 (en) * | 2004-10-18 | 2008-04-08 | Amgen Inc. | Thiadiazole compounds and methods of use |
EP1940802A2 (en) * | 2005-09-22 | 2008-07-09 | Pfizer Products Inc. | Imidazole compounds for the treatment of neurological disorders |
GB0602335D0 (en) * | 2006-02-07 | 2006-03-15 | Remynd Nv | Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases |
US8541406B2 (en) | 2006-02-07 | 2013-09-24 | Nv Remynd | Thiadiazole derivatives for the treatment of neurodegenerative diseases |
GB0623258D0 (en) * | 2006-11-22 | 2007-01-03 | Remynd Nv | Thiadiazole derivatives for the treatment of neuro-degenerative diseases |
GB0704394D0 (en) * | 2007-03-07 | 2007-04-11 | Senexis Ltd | Compounds |
FR2913886B1 (fr) | 2007-03-22 | 2012-03-02 | Guerbet Sa | Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer |
CA2692713A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
WO2009011871A2 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
JP5705748B2 (ja) | 2009-02-18 | 2015-04-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を変調する複素環化合物 |
US8299103B2 (en) * | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
JP2013517271A (ja) | 2010-01-15 | 2013-05-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節する化合物 |
US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
TW202328068A (zh) * | 2021-09-01 | 2023-07-16 | 美商斯普林渥克斯治療有限公司 | 尼羅司他(nirogacestat)之合成 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6114537A (en) | 1996-02-26 | 2000-09-05 | Apotex Inc. | Process for scavenging thiols |
US5962535A (en) * | 1997-01-17 | 1999-10-05 | Takeda Chemical Industries, Ltd. | Composition for alzheimer's disease |
AR039059A1 (es) | 2001-08-06 | 2005-02-09 | Sanofi Aventis | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
BRPI0413709A (pt) | 2003-08-21 | 2006-10-17 | Pfizer Prod Inc | compostos para o tratamento de distúrbios neurodegenerativos |
-
2005
- 2005-03-11 US US11/078,867 patent/US7232820B2/en not_active Expired - Fee Related
- 2005-03-23 JP JP2007505657A patent/JP2007530661A/ja not_active Withdrawn
- 2005-03-23 CA CA002561596A patent/CA2561596A1/en not_active Abandoned
- 2005-03-23 BR BRPI0509504-2A patent/BRPI0509504A/pt not_active IP Right Cessation
- 2005-03-23 MX MXPA06011350A patent/MXPA06011350A/es unknown
- 2005-03-23 EP EP05718290A patent/EP1735294A1/en not_active Withdrawn
- 2005-03-23 WO PCT/IB2005/000801 patent/WO2005095368A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20050222219A1 (en) | 2005-10-06 |
US7232820B2 (en) | 2007-06-19 |
MXPA06011350A (es) | 2006-12-15 |
CA2561596A1 (en) | 2005-10-13 |
JP2007530661A (ja) | 2007-11-01 |
EP1735294A1 (en) | 2006-12-27 |
WO2005095368A1 (en) | 2005-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0509504A (pt) | compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos | |
UA83899C2 (uk) | Сполуки імідазолу для лікування нейродегенеративних розладів | |
BR0314611A (pt) | Compostos de tiazol para o tratamento de distúrbios neurodegenerativos | |
BRPI0509477A (pt) | compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos | |
BRPI0413245A (pt) | compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos | |
BRPI0509515A (pt) | composto, formulação farmacêutica, uso de um composto método para tratamento de doenças, e, processo para a preparação de um composto | |
MXPA05012196A (es) | Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos. | |
UY28484A1 (es) | Compuestos para el tratamiento de trastornos neurodegenerativos | |
BRPI0509464A (pt) | compostos tiazol sulfonamida para o tratamento de distúrbios neurodegenerativos | |
ATE402150T1 (de) | Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen | |
RS20080139A (en) | Imidazole coumpounds for the treatment of neurological disorders | |
BRPI0509582A (pt) | compostos de tiazol-amina e respectivas composições farmacêuticas | |
UY28458A1 (es) | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos | |
BRPI0509386A (pt) | compostos de isoxazol- e isotiazol-amina para o tratamento de distúrbios neurodegenerativos | |
DOP2006000200A (es) | Compuestos de imidazol para el tratamiento de trastonos neurologicos | |
DOP2004000982A (es) | Compuestos para el tratamiento de trastornos neurodegenerativos | |
CU23591B7 (es) | Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2137 DE 20/12/2011. |